Do Meningiomas Grow Back? Factors, Recurrence & Treatment

Meningiomas can and do grow back after treatment, but the likelihood varies enormously depending on the tumor’s biological behavior and how thoroughly it was removed. A low-grade meningioma that is completely resected has roughly a 10% chance of recurring within five years, while an aggressive high-grade tumor may return even after seemingly successful surgery. Understanding what drives recurrence, and what can be done about it, matters because meningiomas are the most common primary brain tumors in adults, and many patients will live with follow-up imaging for years or decades after their initial treatment.

How Tumor Grade Shapes Recurrence Risk

The single strongest predictor of whether a meningioma will come back is its grade under the World Health Organization classification system. Grade 1 tumors, which account for the majority of meningiomas, are the least aggressive. After complete surgical removal, the cumulative recurrence rate for grade 1 tumors is about 10% at five years and 20% at ten years. One large evidence-based review found that no recurrences were observed beyond 11 years of follow-up for completely resected grade 1 meningiomas, even when observation continued for years afterward.¹ That is genuinely reassuring for most patients.

Grade 2 (atypical) meningiomas are a different story. Even when completely resected, roughly a quarter recur within five years, half within ten years, and close to 80% by fifteen years. Grade 3 (anaplastic or malignant) meningiomas are the most concerning: about 62% recur within five years of complete resection, and in one cohort, every single grade 3 tumor had recurred by ten years.¹ Other estimates place ten-year recurrence for grade 2 tumors at 20–30% and grade 3 tumors at 70–80%, with the variation reflecting differences in how completely tumors were removed across different studies.²

Why How Much the Surgeon Removes Matters So Much

Neurosurgeons have long used the Simpson grading system to describe how thoroughly a meningioma was resected, ranging from grade I (the tumor plus its dural attachment and any involved bone are all removed) down to grade IV (only a partial removal). The relationship between resection extent and recurrence is striking. In one large study, grade I resection carried only a 5% recurrence rate, while grade IV resection saw recurrence climb to 35%.³

A separate analysis found that a Simpson grade II resection (where tumor is removed but the dural attachment is only cauterized rather than excised) more than doubled the ten-year recurrence rate compared with grade I, from about 8.5% to nearly 19%. The impact of more aggressive resection was even more pronounced in higher-grade meningiomas.⁴ This is why surgeons aim for the most complete removal safely achievable. But “safely achievable” is the key phrase: when a tumor wraps around critical blood vessels or sits deep in the skull base, pursuing a grade I resection can risk serious neurological damage, and a deliberate subtotal removal may be the wiser choice.

Where the Tumor Sits in the Brain

Meningiomas at the skull base tend to behave differently from those on the brain’s convexity (the outer, more accessible surface). Skull base tumors are harder to remove completely because they sit near cranial nerves and major arteries, and they also appear to have a biologically higher tendency to progress. One study found that the overall progression rate for skull base meningiomas was 33% compared with about 20% for non-skull-base tumors. The five-year progression-free survival was 60% for skull base tumors versus 80% for those located elsewhere.⁵

A large cohort study of over 1,200 patients confirmed skull base location as an independent risk factor for recurrence. Interestingly, this risk persisted even years after surgery: skull base location remained a predictor of recurrence in patients who had already been recurrence-free for three and five years, meaning these tumors can come back late.⁶ The same study identified male sex and high-grade histology as additional independent predictors, with high-grade tumors carrying roughly three and a half times the hazard of recurrence.

Molecular Markers That Predict Aggressive Behavior

Tumor grade under the microscope tells you a lot, but it does not tell you everything. Two tumors that look identical under the microscope can behave very differently, and researchers have been working to understand why at a molecular level.

One of the most powerful molecular predictors discovered so far involves mutations in the TERT gene promoter. TERT helps maintain telomeres, the protective caps on chromosomes, and when it becomes overactive it essentially lets tumor cells keep dividing indefinitely. In meningiomas, patients with TERT promoter mutations had a median time to progression of just 10 months, compared with about 15 years for patients without the mutation.⁷ That is an extraordinary gap. While TERT mutations are relatively uncommon in meningiomas overall, when present they signal a tumor that is likely to return quickly and aggressively.

The Ki-67 index, which measures how actively tumor cells are dividing, also has predictive value. A meta-analysis found that higher Ki-67 levels were tied to roughly two and a half times the hazard of disease progression or recurrence.⁸ One nuanced finding is that Ki-67 may be less about whether a tumor recurs and more about how quickly. One study found that tumors with a Ki-67 below 4% took a median of nearly five years to recur, while those above that threshold recurred within months.⁹ For grade 2 meningiomas specifically, a Ki-67 cutoff around 7.5% has been proposed as a threshold where recurrence risk climbs substantially.¹⁰

The most common genetic alteration in meningiomas is loss of the NF2 gene, which occurs across both low- and high-grade tumors. Meningiomas that retain NF2 function tend to carry different driver mutations, including changes in genes called TRAF7, KLF4, AKT1, and SMO, and these NF2-wildtype tumors are more frequently benign.¹¹ The practical relevance here is that not all meningiomas are created equal at the genetic level, and knowing the mutation profile helps predict behavior.

DNA Methylation as a Better Crystal Ball

Perhaps the most promising recent advance in predicting meningioma recurrence comes from DNA methylation profiling. Methylation is a chemical modification of DNA that affects how genes are turned on or off without changing the underlying genetic code, and it turns out that the overall methylation pattern of a meningioma captures information about its biology that traditional microscopic grading misses.

Researchers developed a methylation-based recurrence predictor that performed significantly better than the standard WHO grading system at forecasting which tumors would come back within five years. The tool carried roughly three and a half times the hazard ratio for recurrence even after accounting for tumor grade, extent of resection, and chromosomal abnormalities.¹² A recent multicenter validation study confirmed that both the original and an updated next-generation version of this predictor outperformed WHO grading, with the newer model using far fewer DNA probes and thus being more practical for clinical use.¹³

This matters clinically because methylation profiling could change how patients are monitored after surgery. A grade 2 tumor flagged as low-risk by its methylation profile might need less intensive follow-up, while a grade 1 tumor flagged as high-risk might deserve closer watching or even early additional treatment. These tools are not yet standard of care everywhere, but they are increasingly being adopted at academic centers.

Radiation Therapy to Prevent Recurrence

When a meningioma cannot be completely removed, or when its grade and molecular features suggest high recurrence risk, radiation therapy can be added after surgery. For low-grade tumors that were only partially resected, combined proton and photon radiation has produced impressive results, with one long-term series reporting a recurrence-free rate of 100% at five years and 88% at ten years.¹⁴

For higher-grade meningiomas, adjuvant radiation after surgery is more commonly recommended, though the evidence base is less definitive because randomized trials are scarce. The available data suggests that incomplete resection combined with lower radiation doses leads to worse tumor control.¹⁵ Stereotactic radiosurgery (focused, high-dose radiation delivered in one or a few sessions) for incompletely resected atypical and anaplastic meningiomas has shown tumor control rates of around 91% at three years for grade 2 tumors, declining to about 81% at ten years. For grade 3 tumors, control rates were lower: about 77% at three years and 60% at ten years.¹⁶

What Happens When a Meningioma Does Come Back

Recurrence does not mean the situation is hopeless, but treatment does become more complex. Repeat surgery is the most straightforward option when the tumor is accessible. A study examining outcomes of re-do surgery for recurrent meningiomas found that complication rates for things like postoperative bleeding and infection were comparable between the first and second operations. However, the rate of neurological worsening was notably higher after repeat surgery: about 17% of patients experienced new or worsened neurological deficits after a second operation, compared with about 4% after the initial surgery.¹⁷ Scar tissue, altered anatomy, and the tumor’s tendency to invade structures it previously only compressed all contribute to this increased surgical risk.

For tumors that have already been irradiated, re-irradiation is an option that is increasingly studied. A systematic review and meta-analysis of re-irradiated meningiomas found a local control rate of about 53% and an overall survival rate of about 73%. The rate of symptomatic radiation necrosis (where healthy brain tissue is damaged by the radiation) was around 8%, and severe toxicity was uncommon.¹⁸ Another series using particle radiation for re-irradiation reported 71% progression-free survival at one year and a median progression-free survival of about 34 months, with no severe or life-threatening side effects.¹⁹

Systemic therapies (drugs given by mouth or intravenously) for recurrent meningiomas have been studied extensively but remain disappointing overall. A systematic review catalogued the full range of approaches that have been tried, including traditional chemotherapy agents, angiogenesis inhibitors, somatostatin receptor analogs, and targeted kinase inhibitors.²⁰ None has emerged as reliably effective, and drug therapy for meningioma remains largely in the clinical trial space. Patients with multiply recurrent tumors who have exhausted surgical and radiation options are often encouraged to seek enrollment in trials exploring new molecular targets.

How Long You Need to Keep Watching

One of the most common practical questions after meningioma treatment is how long follow-up MRI scans need to continue. The answer depends entirely on grade. For completely resected grade 1 tumors, the reassuring finding that no recurrences were seen beyond 11 years in one large analysis suggests that a decade or so of imaging may be sufficient for truly low-risk patients. Still, a separate long-term study of benign meningiomas treated with radiation found that most recurrences actually presented at least ten years after treatment, with the actuarial recurrence rate climbing from 3% at ten years to 8% at twenty years.²¹ So while late recurrence is uncommon for grade 1 tumors, it is not unheard of, and the optimal surveillance duration remains a judgment call that balances the small risk of a late surprise against the cost and anxiety of ongoing scans.

Grade 2 tumors demand longer and more frequent monitoring because recurrences can continue appearing well beyond a decade after surgery. Grade 3 tumors, where nearly all eventually recur, require the most vigilant follow-up, and imaging is typically continued indefinitely.

When a scan shows something growing in an area that was previously treated with radiation, telling the difference between true tumor recurrence and radiation necrosis (damaged but non-cancerous tissue from the treatment itself) can be genuinely difficult on standard MRI. A large diagnostic meta-analysis found that standard MRI was actually the least useful modality for distinguishing these two entities. More advanced techniques, including MR spectroscopy and single photon emission computed tomography, performed considerably better, with MR spectroscopy achieving the highest sensitivity at about 91%.²² If your follow-up MRI is ambiguous, requesting one of these additional imaging studies is reasonable.

Radiation-Induced Meningiomas

People who received radiation to the head earlier in life, whether for childhood leukemia, another brain tumor, or even ringworm treatment decades ago, face an elevated risk of developing meningiomas years to decades later. These radiation-induced meningiomas tend to be biologically more aggressive than their spontaneous counterparts. A systematic review and meta-analysis of over 900 such tumors found a pooled recurrence rate of about 27%, roughly two to three times higher than the rate for spontaneous meningiomas.²³ Genetically, these tumors tend to be driven by NF2 alterations and carry certain epigenetic changes, including loss of a histone mark called H3K27me3, that correlate with more aggressive behavior.²⁴ If you have a history of cranial radiation, your neurosurgeon will likely monitor you more closely and consider a lower threshold for additional treatment after surgery.

Hormonal Factors and Sex Differences

Meningiomas are about twice as common in women as in men, and most meningiomas express progesterone receptors, with some studies reporting expression in over 90% of tumors. Higher progesterone receptor expression has generally been linked to a more favorable prognosis and lower recurrence risk, though findings have not been entirely consistent across studies.²⁵ Male sex, as mentioned earlier, has been identified as an independent risk factor for recurrence in large cohort studies, which may partly reflect the fact that meningiomas in men are more often higher grade and more frequently lack progesterone receptors.

The relationship between hormone replacement therapy, oral contraceptives, and meningioma risk or recurrence has attracted considerable attention but remains complex. If you are a meningioma patient considering hormonal therapy for any reason, this is worth discussing specifically with your treatment team.

When Meningiomas Shrink on Their Own

In rare circumstances, meningiomas can spontaneously regress without any treatment. A documented case followed over roughly 17 years with serial imaging showed a meningioma that went through an initial slow-growth phase, then enlarged, and then shrank on its own as it progressively calcified.²⁶ This is emphatically not the norm and should not be counted on as a management strategy. But it illustrates that meningiomas are not static growths; they can undergo dynamic biological changes over time, including periods of dormancy. This is one reason why the “watch and wait” approach with serial imaging is a legitimate management strategy for small, asymptomatic, incidentally discovered meningiomas, particularly in older patients.

Quality of Life After Repeat Treatment

Recurrence and its treatment can take a cumulative toll. Beyond the neurological risks of repeat surgery already discussed, a systematic review of quality-of-life outcomes after skull base tumor resection found that both radiotherapy and recurrent surgeries were predictors of poorer quality of life.²⁷ Fatigue, cognitive changes, and cranial nerve deficits (such as facial weakness, hearing loss, or double vision) can accumulate with each intervention. This is why the decision about how aggressively to treat a recurrence is not purely an oncological calculation; it weighs the biological threat of the tumor against the functional cost of additional treatment, and that balance is different for every patient.

For older patients with slow-growing recurrences, observation with imaging alone may be entirely appropriate. For younger patients with aggressive tumors, pushing for maximum treatment even with its risks may offer the best long-term outcome. The conversation between patient and neurosurgeon is where all of these factors come together, and it should be an honest one about both the disease and the side effects of fighting it.